Research Lead | Development Opportunity
BioFocus DPI, part of Galapagos NV, of Mechelen, Belgium, launched the US National Institutes of Health Clinical Compound Collection (NCC) of 446 bioactive compounds, most of which are known drugs.
The compounds are available to universities, companies and qualified individuals as a pre-formatted set through BioFocus DPI.
“We are pleased to be handling the Clinical Compound Collection for the NIH. The majority of the compounds in this collection are not provided in typical commercial offerings, representing a fantastic resource for biomedical research,” said Dan Harvey, Senior Director of BioFocus DPI.
“Furthermore we ensure that these high-quality compounds are delivered to researchers quickly, and that they retain their tested purity.”
The NCC is managed and distributed through BioFocus DPI’s Compound Management facility, based in South San Francisco.
NCC consists of a plated array of small molecules, centered on those with a history of use in human clinical trials. The collection was assembled by the NIH through the Molecular Libraries Roadmap Initiative, as part of its mission to expand the use of compound screening in biomedical research.
Similar collections of FDA-approved drugs have proved to be rich sources of undiscovered bioactivity and therapeutic potential. The clinically focused NCC set contains known drugs and related highly drug-like compounds, which can provide starting points for chemical annotation of targets and biological pathways.
Similar collections have enabled the identification of drugs that are effective and even directly applicable to important new diseases.
The NIH Molecular Libraries Small Molecule Repository (MLSMR) collects samples for high throughput biological screening and distributes them to the NIH Molecular Libraries Screening Center Network.
Compound Focus, Inc. a wholly owned subsidiary of BioFocus DPI operates compound management services at its South San Francisco site, home to the MLSMR.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
